SCYX Q2 2025 Earnings — SCYNEXIS, Inc. Revenue & Financial Results | Market Cap Arena

SCYXSCYNEXIS, Inc.

$38M

Q2 2025 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$1M+85.3% YoY

Gross Profit

$1M100.0% margin

Operating Income

-$10M-701.0% margin

Net Income

-$7M-504.8% margin

EPS (Diluted)

$-0.14

QoQ Revenue Growth

+430.7%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$7M

Stock-Based Comp.

$820,000

Balance Sheet

Total Assets

$61M

Total Liabilities

$16M

Stockholders' Equity

$44M

Cash & Equivalents

$11M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$1M	$736,000	+85.3%
Gross Profit	$1M	$736,000	+85.3%
Operating Income	-$10M	-$9M	-3.5%
Net Income	-$7M	-$14M	+52.4%

Revenue Segments

License and Service

$1M100%